Aurobindo Pharma receives USFDA approval for gastro reflux drug
The company said the launch of the product is based on the settlement terms/litigation outcome with AstraZeneca.
Drug firm Aurobindo Pharma has received final approval from USFDA to manufacture and market Esomeprazole Magnesium delayed release capsules, used in a treatment of gastroesophageal reflux disease, in the American market.
The company said the launch of the product is based on the settlement terms/litigation outcome with AstraZeneca.
"The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Esomeprazole Magnesium delayed-release capsules USP, 20 mg and 40 mg," Aurobindo Pharma said in a Bombay Stock Exchange (BSE) filing.
The approved abbreviated new drug application (ANDA) is a bio-equivalent and therapeutically equivalent to the reference listed drug product Nexium delayed-release capsules USP, 20 mg and 40 mg, of AstraZeneca Pharmaceuticals, it added.
"The approved product has an estimated market size of $4.2 billion (nearly Rs 27,941.6 crore) for the 12 months ended February 2016, according to IMS," it said.
Esomeprazole Magnesium delayed-release capsules is used in a treatment of gastroesophageal reflux disease.
Aurobindo Pharma currently has a total of 253 ANDA approvals -- 217 final approvals including 10 from Aurolife Pharma LLC and 36 tentative -- from the USFDA.
At 13:32 hours, on Friday, the shares of Aurobindo Pharma were trading up 2.40% or Rs 18.45 at Rs 786.10 per scrip on the BSE.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
IPL Auction 2025 Free Live Streaming: When and where to watch Indian Premier League 2025 mega auction live online, on TV, Mobile Apps, and Laptop?
Tamil Nadu Weather Alert: Chennai may receive heavy rains; IMD issues yellow & orange alerts in these districts
SIP vs PPF: How much corpus you can build in 15 years by investing Rs 1.5 lakh per year? Understand through calculations
SBI Senior Citizen Latest FD Rates: What senior citizens can get on Rs 7 lakh, Rs 14 lakh, and Rs 21 lakh investments in Amrit Vrishti, 1-, 3-, and 5-year fixed deposits
01:55 PM IST